BULEVIRTIDE

BULEVIRTIDE was reported 96 times

These side effects are most commonly reported by patients taking BULEVIRTIDE:

# Side effect Count
0 HEPATIC CIRRHOSIS 14
1 PANCYTOPENIA 10
2 ASTHENIA 7
3 DRUG INEFFECTIVE 7
4 HEPATITIS D 6
5 VIROLOGIC FAILURE 6
6 FATIGUE 5
7 HEPATIC FAILURE 5
8 HEPATIC FIBROSIS 5
9 THROMBOCYTOPENIA 5
10 TREATMENT NONCOMPLIANCE 5
11 DRUG-INDUCED LIVER INJURY 4
12 HEPATOCELLULAR CARCINOMA 4
13 LICHEN PLANUS 4
14 OFF LABEL USE 4
15 PANCREATITIS ACUTE 4
16 PORTAL HYPERTENSION 4
17 VIRAL LOAD INCREASED 4
18 ALANINE AMINOTRANSFERASE ABNORMAL 3
19 DISEASE PROGRESSION 3
20 HEPATITIS D RNA POSITIVE 3
21 INFLUENZA LIKE ILLNESS 3
22 INJURY ASSOCIATED WITH DEVICE 3
23 LEUKOPENIA 3
24 LIVER TRANSPLANT 3
25 NEUTROPENIA 3
26 PRURITUS 3
27 ALANINE AMINOTRANSFERASE INCREASED 2
28 CONDITION AGGRAVATED 2
29 COVID-19 2
30 DYSPNOEA 2
31 HEADACHE 2
32 HEPATIC ENZYME INCREASED 2
33 HYPOMANIA 2
34 LIVER DISORDER 2
35 LIVER FUNCTION TEST INCREASED 2
36 MATERNAL EXPOSURE DURING PREGNANCY 2
37 PORTAL VEIN THROMBOSIS 2
38 TOTAL BILE ACIDS INCREASED 2
39 TRANSAMINASES INCREASED 2
40 VARICES OESOPHAGEAL 2
41 VIRAL INFECTION 2
42 ABNORMAL UTERINE BLEEDING 1
43 ACUTE PSYCHOSIS 1
44 APPENDICITIS 1
45 ASTROCYTOMA 1
46 B-CELL LYMPHOMA 1
47 BILE ACIDS INCREASED 1
48 BLOOD ALBUMIN INCREASED 1
49 BLOOD BILIRUBIN ABNORMAL 1
50 BLOOD BILIRUBIN DECREASED 1
51 BLOOD GLUCOSE INCREASED 1
52 BONE PAIN 1
53 BREAST CANCER 1
54 CHOLANGITIS 1
55 CHOLESTASIS 1
56 CHRONIC GASTRITIS 1
57 CHRONIC SINUSITIS 1
58 CUTANEOUS SYMPTOM 1
59 DEATH 1
60 DECREASED APPETITE 1
61 DEPRESSION 1
62 DEPRESSIVE SYMPTOM 1
63 DERMATITIS ALLERGIC 1
64 DISTURBANCE IN ATTENTION 1
65 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1
66 DRUG INTERACTION 1
67 DUODENITIS 1
68 DYSGEUSIA 1
69 EPILEPSY 1
70 FULL BLOOD COUNT DECREASED 1
71 HAEMOGLOBIN DECREASED 1
72 HAEMORRHAGE 1
73 HEAD DISCOMFORT 1
74 HEPATIC CANCER 1
75 HEPATIC ENCEPHALOPATHY 1
76 HEPATIC FIBROSIS MARKER INCREASED 1
77 HEPATIC FUNCTION ABNORMAL 1
78 HEPATITIS ACUTE 1
79 HEPATITIS B DNA ASSAY POSITIVE 1
80 HEPATITIS B DNA INCREASED 1
81 HEPATITIS D ANTIBODY POSITIVE 1
82 HYPERSENSITIVITY 1
83 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 1
84 INFUSION SITE THROMBOSIS 1
85 INJECTION SITE DERMATITIS 1
86 INJECTION SITE ERYTHEMA 1
87 INJECTION SITE MASS 1
88 INJECTION SITE PRURITUS 1
89 INJECTION SITE REACTION 1
90 INJECTION SITE SWELLING 1
91 INJECTION SITE WARMTH 1
92 INTENTIONAL DOSE OMISSION 1
93 INTERNATIONAL NORMALISED RATIO DECREASED 1
94 IRON DEFICIENCY ANAEMIA 1
95 LOCALISED INFECTION 1
96 LYMPHOPENIA 1
97 METASTASES TO LYMPH NODES 1
98 NASAL CYST 1
99 NAUSEA 1
100 OESOPHAGEAL VARICES HAEMORRHAGE 1
101 PAIN 1
102 PANCREATITIS 1
103 PERIPHERAL SWELLING 1
104 PLATELET COUNT DECREASED 1
105 POLYNEUROPATHY 1
106 PORTAL HYPERTENSIVE GASTROPATHY 1
107 PRODUCT DOSE OMISSION ISSUE 1
108 PRODUCT QUALITY ISSUE 1
109 PRODUCT USE IN UNAPPROVED INDICATION 1
110 PROTHROMBIN TIME PROLONGED 1
111 PYREXIA 1
112 REBOUND EFFECT 1
113 RENAL IMPAIRMENT 1
114 RESPIRATORY DISTRESS 1
115 SHOCK HAEMORRHAGIC 1
116 SLEEP DISORDER 1
117 SPONTANEOUS BACTERIAL PERITONITIS 1
118 SUICIDAL BEHAVIOUR 1
119 SUSPECTED PRODUCT CONTAMINATION 1
120 TREATMENT FAILURE 1
121 TYPE I HYPERSENSITIVITY 1
122 URINARY TRACT INFECTION 1
123 URTICARIA 1
124 VIRAEMIA 1
125 VITAMIN D DEFICIENCY 1
126 VITREOUS DETACHMENT 1
127 WHITE BLOOD CELL COUNT DECREASED 1